Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anthem BiosciencesNSE:ANTHEM +2.68%24 Return-on-Tangible-Equity is 15.77% as of Jun. 2026, which is 27% below its 10-year median of 21.72. GuruFocus rates NSE:ANTHEM with a GF Score™ of 24/100. The stock has 5 warning signs investors should review. Among 1,198 Biotechnology companies, Anthem Biosciences ranks better than 91.4% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Anthem Biosciences's annualized net income for the quarter that ended in Jun. 2026 was ₹4,798 Mil. Anthem Biosciences's average shareholder tangible equity for the quarter that ended in Jun. 2026 was ₹30,421 Mil. Therefore, Anthem Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2026 was 15.77%.
The historical rank and industry rank for Anthem Biosciences's Return-on-Tangible-Equity or its related term are showing as below:
NSE:ANTHEM'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 20.13 Med: 21.72 Max: 30.08
Current: 21.08
During the past 5 years, Anthem Biosciences's highest Return-on-Tangible-Equity was 30.08%. The lowest was 20.13%. And the median was 21.72%.
NSE:ANTHEM's Return-on-Tangible-Equity is ranked better than 91.4% of 1198
companies
in the Biotechnology industry
Industry Median: -42.305
vs NSE:ANTHEM: 21.08
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Anthem Biosciences Return-on-Tangible-Equity Related Terms
Anthem Biosciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Anthem Biosciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ANTHEM vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Anthem Biosciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anthem Biosciences Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anthem Biosciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Anthem Biosciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Jun. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 15.77% mean?
Anthem Biosciences (NSE:ANTHEM) has a Return-on-Tangible-Equity of 15.77% as of Jun. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Anthem Biosciences and its competitors. This is 27% below median its historical median of 21.72. Over the past decade, Anthem Biosciences' Return-on-Tangible-Equity has ranged from 20.13 to 30.08. According to the industry distribution chart, Anthem Biosciences ranks #103 out of 1198 companies in the Biotechnology industry, placing it in the top 8.6%.
Is Anthem Biosciences' Return-on-Tangible-Equity too high?
Anthem Biosciences' current Return-on-Tangible-Equity of 15.77% is 27% below median its 10-year median of 21.72. Over the past 10 years, this metric has ranged from a low of 20.13 to a high of 30.08. Based on the distribution chart, Anthem Biosciences ranks #103 out of 1198 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Anthem Biosciences has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anthem Biosciences' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Anthem Biosciences ranks #103 out of 1198 companies for Return-on-Tangible-Equity. This places Anthem Biosciences in the top 9% of its industry — outperforming the majority of peers. Historically, Anthem Biosciences' own Return-on-Tangible-Equity has ranged from 20.13 to 30.08 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Anthem Biosciences and its competitors. Anthem Biosciences's current Return-on-Tangible-Equity is 15.77%, which is 27% below median its own 10-year median of 21.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anthem Biosciences stock overvalued right now?
Anthem Biosciences (NSE:ANTHEM) has a current Return-on-Tangible-Equity of 15.77%. The current Return-on-Tangible-Equity is 15.77%, which is 27% below median its 10-year median of 21.72. Anthem Biosciences' overall GF Score™ is 24/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Anthem Biosciences (NSE:ANTHEM), the current Return-on-Tangible-Equity is 15.77% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anthem Biosciences Ltd is an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. It is one of the few companies in India with integrated New Chemical Entity (NCE) and New Biological Entity (NBE) capabilities across drug discovery, development, and commercial manufacturing. As a one-stop service provider, It serves a range of customers, encompassing innovator-focused emerging biotech and large pharmaceutical companies globally.
24GF Score
Get the complete analysis for NSE:ANTHEM
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ANTHEM has been successfully added to your 
